Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

All: Soft Tissue

A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

The purpose of this study is to see if aldoxorubicin (the study drug) will slow cancer growth and also to evaluate the side effects of the treatment. Aldoxorubicin is a pro-drug of an approved chemotherapy drug called doxorubicin. Pro-drugs are inactive forms of a drug that only become active once inside the body.

Status: Accepting New Patients
Principal Investigator: Agulnik

A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.

Status: Accepting New Patients
Principal Investigator: Agulnik

A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing–Like Sarcomas

The purpose of this study is to compare the safety (side effects) and effectiveness of giving participants the study drug regorafenib versus a placebo (sugar pill).

Status: Accepting New Patients
Principal Investigator: Agulnik

Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (OER-SAR-043)

The goal of this study is to find out what effects, good and/or bad, pazopanib has on patients and their angiosarcoma.

Status: Accepting New Patients
Principal Investigator: Agulnik

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma.

Status: Accepting New Patients
Principal Investigator: Agulnik

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed By Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

In this study, researchers are determining if giving chemotherapy with gemcitabine plus docetaxel, followed by doxorubicin, to patients whose leiomyosarcoma was located only in the uterus, decreases the chance that the leiomyosarcoma will return.

Status: Accepting New Patients
Principal Investigator: Berry

Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients with Soft Tissue Sarcoma

The purpose of this study is to test the safety and effectiveness of a drug called GPX-150.

Status: Accepting New Patients
Principal Investigator: Agulnik

Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

The goal of this study is to find out what effects (good and/or bad) pazopanib given with both chemotherapy and radiation therapy has on people with intermediate and high risk non-Rhabdomyosarcoma soft tissue sarcomas (NRSTS).

Status: Accepting New Patients
Principal Investigator: Agulnik

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

The purpose of this study is to determine out if a change in diet and exercise in women with ovarian, fallopian tube, or primary peritoneal cancer, has an effect on the length of time patients are cancer-free following initial treatment.

Status: Accepting New Patients
Principal Investigator: Berry

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors Module 8 – LEE011 for Patients with CDK4/6 Pathway Activated Tumors

Researchers want to know if LEE011 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a CDK4/6 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: Victorson

Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given alone or in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).

Status: Accepting New Patients
Principal Investigator: Chae

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer

The first purpose of this study is to compare the combination of carboplatin, paclitaxel and bevacizumab to the standard combination of carboplatin and paclitaxel alone. A second purpose of this study is to determine if a second surgery to remove tumor followed by chemotherapy can increase the time that patients remain disease free.

Status: Accepting New Patients
Principal Investigator: Berry

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: Kalapurakal

A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

The purpose of this study is twofold. The first purpose is to evaluate if the addition of vincristine/topotecan/cyclophosphamide (VTC) to standard chemotherapy can improve the treatment of Ewing sarcoma. The second purpose is to find out if PET scans could be useful in evaluating the beneficial effects of the treatment.

Status: Accepting New Patients
Principal Investigator: Walterhouse

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Kumthekar

last updated: Thu - March 05, 2015 - 05:58 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.